This website was developed by Paratek Medical Affairs professionals as a resource for healthcare professionals practicing in the United States.
The information provided on this website is for informational purposes and is not intended to promote the use of any product.
SAWC Spring
April 30-May 4, 2025
Grapevine, TX
American Thoracic Society
May 16-21, 2025
San Francisco, CA
Colorado Mycobacterium Conference
May 27-30, 2025
Fort Collins, CO
ASM Microbe
June 19-23, 2025
Los Angeles, CA
The below non-CME program was supported by Paratek Pharmaceuticals, Inc
WOUNDS
Skin and Soft Tissue Infections: Current Trends and Treatment Challenges of Oral Antibiotic Therapies
Objectives:
1. Review the epidemiology of acute bacterial skin and skin structure infections.
2. Describe the in vitro activity of guideline-recommended oral antibiotics against common and other less common causative pathogens.
3. Discuss the in vitro activity of guideline-recommended antibiotics and associated treatment outcomes.
4. Discuss considerations in treatment selection based on current clinical practice guidelines.
Available until September 9, 2025
--------------------------------------------------------------------------------------------------------------------------------------------------------------------
The below CME program was supported by an independent educational grant from Paratek Pharmaceuticals, Inc. The materials presented in the CME program was not created or influenced by Paratek and do not reflect the views of Paratek. These materials may discuss uses and dosages for therapeutic products that may not be approved by the FDA and are not intended to promote any product or indication outside of an FDA-approved use. Prescribers should consult the FDA-approved Prescribing Information for each individual product.
Please check back for updates
By completing this form, I verify that I requested this information completely independently and solely for my own evaluation and application to my practice, patients, or general education, or for the pharmacy and therapeutics committee. I affirm that my request was in no way prompted by Paratek Pharmaceuticals or any representative of Paratek.
